Darapladib

CAT:
804-HY-10521-01
Size:
5 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Darapladib - image 1

Darapladib

  • Description :

    Darapladib (SB-480848) is an orally active, selective and reversible Lp-PLA2 inhibitor (IC50=0.25 nM) . Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer[1][2][3][4].
  • Product Name Alternative :

    SB-480848
  • UNSPSC :

    12352005
  • Hazard Statement :

    H302, H315, H319, H335
  • Target :

    Apoptosis; Phospholipase
  • Type :

    Reference compound
  • Related Pathways :

    Apoptosis; Metabolic Enzyme/Protease
  • Applications :

    COVID-19-immunoregulation
  • Field of Research :

    Cancer; Cardiovascular Disease
  • Assay Protocol :

    https://www.medchemexpress.com/Darapladib.html
  • Purity :

    99.92
  • Solubility :

    DMSO : ≥ 100 mg/mL
  • Smiles :

    FC1=CC=C(CSC(N(CC(N(CCN(CC)CC)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)=O)C4=C5CCC4)=NC5=O)C=C1
  • Molecular Formula :

    C36H38F4N4O2S
  • Molecular Weight :

    666.77
  • Precautions :

    H302, H315, H319, H335
  • References & Citations :

    [1]Blackie JA, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett. 2003 Mar 24;13 (6) :1067-70.|[2]Hu MM, et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis inLDLR-deficient mice. Acta Pharmacol Sin. 2011 Oct;32 (10) :1253-1258.|[3]Wang YJ, et al. The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction. Toxicol Appl Pharmacol. 2020 Sep 1;402:115133. |[4]Riley RF, et al. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. IDrugs. 2009 Oct;12 (10) :648-55.
  • Shipping Conditions :

    Room Temperature
  • Storage Conditions :

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category :

    Reference compound1
  • Clinical Information :

    Phase 3
  • CAS Number :

    [356057-34-6]

Featured Selection

Popular Products

Discover our most sought-after biotechnology products, trusted by researchers worldwide